Date: 2015-03-25
Type of information: Grant
Company: Horizon Discovery (UK)
Investors: Department for Business, Innovation and Skills (UK) Innovate UK (UK) Birmingham City Council (UK)
Amount: £6.2 million
Funding type: grant
Planned used: The AMSCI program consists of an approximate total £11.3M of costs with approximately £6.2 million in grant funding being delivered by the UK Government Department for Business, Innovation and Skills, Innovate UK and Birmingham City Council, to support the future needs of biologics manufacturing in the UK. Horizon will receive up to £652,000 which will be used to expand research performed in its Bioproduction business. This initiative will support the future needs of biologics manufacturing and will help develop next-generation production systems so that the most efficacious and cost-effective therapies are made available to patients.
Horizon will use its gene editing and screening expertise to develop a high throughput platform designed to accelerate the development of novel and improved Chinese Hamster Ovary (CHO) cell lines. Horizon will introduce specific genetic changes into these CHO cell lines, allowing better decisions to be made on potential performance improvements for biologic drug manufacturing.
Others: * On March 25, 2015, Horizon Discovery, the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, announced that a consortium led by the Centre for Process Innovation (CPI) on behalf of UCB Celltech and Lonza Biologics and including Horizon as a full partner, have been awarded £6.2 million as part of the Advanced Manufacturing Supply Chain Initiative (AMSCI).
Therapeutic area: Technology - Services
